Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules November 8, 2021 Press Releases
Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules November 3, 2021 Press Releases
Oramed Announces Oravax’s Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial October 29, 2021 Press Releases
Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference September 23, 2021 Press Releases
Oramed’s Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment September 15, 2021 Press Releases
Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 9, 2021 Press Releases
Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials August 24, 2021 Press Releases
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism August 16, 2021 Press Releases
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021 August 5, 2021 Press Releases
